pharmabiz.com
Eli Lilly presents positive results from VIVID-2 open-label extension study of Omvoh to treat Crohn's disease at Crohn's and Colitis Congress
These are multi‑year clinical results for a newly approved IL‑23p19 inhibitor (mirikizumab) showing sustained clinical and endoscopic benefit for many patients with moderate‑to‑severe Crohn’s disease, including some who previously failed biologics.
That matters for patients and clinicians considering long‑term treatment options and durability of response.
Adults with moderate‑to‑severe Crohn’s disease, people who have failed prior biologic therapies, clinicians who treat IBD, and researchers following IL‑23 targeted treatments.
What To Know
What to know Eli Lilly reported two‑year results from the VIVID‑2 open‑label extension of the phase 3 VIVID‑1 trial for Omvoh (mirikizumab‑mkrz) in moderately to severely active Crohn’s disease.
The press release/coverage says most patients on continuous treatment achieved or maintained clinical remission and endoscopic response/remission at two years, including some with prior biologic failure.
Safety over the second year was described as generally consistent with the known profile, with a small percentage reporting serious adverse events and few discontinuations for adverse events.
The study population included patients who were randomized to Omvoh in VIVID‑1 and continued into VIVID‑2 after achieving endoscopic response at one year; reported outcomes use both observed-case and modified non‑responder imputation analyses.
The article also notes FDA approval of Omvoh for Crohn’s disease (January 2025) and prior approvals/filings for ulcerative colitis and other jurisdictions. If you want the original data, read the full Lilly presentation or the conference abstract at Crohn’s and Colitis Congress linked in the article.
The press release summarizes percentages for maintained remission/response but does not include full study tables, patient numbers, or detailed safety event descriptions.
This article is a company report of results presented at a conference; it summarizes key percentages but does not present full data tables or independent peer review.
Open‑label extension studies enroll participants who completed the prior trial and can be affected by selection and missing‑data methods; consult the full study presentation or peer‑reviewed publication for complete methods and safety details.
